The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars

Overview

Journal Front Psychol

Date 2021 Feb 15

PMID 33584474

Citations 2

Authors

Davide Mazzoni

Claudia Vener

Ketti Mazzocco

Dario Monzani

Gabriella Pravettoni

Affiliations

Soon will be listed here.

Citing Articles

Stakeholder perspectives on the sustainability of the United States biosimilars market.

Sullivan S, Humphreys S, Fox D, Lockhart C, Tait-Dinger A, Betancourt J J Manag Care Spec Pharm. 2024; 30(10):1065-1072.

PMID: 39012302 PMC: 11424910. DOI: 10.18553/jmcp.2024.24104.

Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.

Alnaqbi K, Al Adhoubi N, Aldallal S, Al Emadi S, Al-Herz A, El Shamy A BioDrugs. 2024; 38(3):449-463.

PMID: 38402494 PMC: 11055752. DOI: 10.1007/s40259-023-00642-1.

References

Marzorati C, Pravettoni G . Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes. J Multidiscip Healthc. 2017; 10:101-106. PMC: 5367583. DOI: 10.2147/JMDH.S122383. View

Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M . Interchangeability of Biosimilars: A European Perspective. BioDrugs. 2017; 31(2):83-91. DOI: 10.1007/s40259-017-0210-0. View

Armuzzi A, Avedano L, Greveson K, Kang T . Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. J Crohns Colitis. 2018; 13(2):259-266. PMC: 6357893. DOI: 10.1093/ecco-jcc/jjy150. View

Rezk M, Pieper B . Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatol Ther. 2017; 4(2):209-218. PMC: 5696297. DOI: 10.1007/s40744-017-0085-z. View

Muskens W, Rongen-van Dartel S, Teerenstra S, Adang E, van Riel P . One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. Rheumatol Adv Pract. 2020; 4(2):rkaa042. PMC: 7519774. DOI: 10.1093/rap/rkaa042. View

OCallaghan J, Bermingham M, Leonard M, Hallinan F, Morris J, Moore U . Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017; 88:252-261. DOI: 10.1016/j.yrtph.2017.06.013. View

Gorini A, Pravettoni G . An overview on cognitive aspects implicated in medical decisions. Eur J Intern Med. 2011; 22(6):547-53. DOI: 10.1016/j.ejim.2011.06.008. View

Odinet J, Day C, Cruz J, Heindel G . The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. J Manag Care Spec Pharm. 2018; 24(10):952-959. PMC: 10398229. DOI: 10.18553/jmcp.2018.24.10.952. View

Kristensen L, Alten R, Puig L, Philipp S, Kvien T, Mangues M . Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs. 2018; 32(5):397-404. PMC: 6182448. DOI: 10.1007/s40259-018-0306-1. View

10.

Pasina L, Casadei G, Nobili A . A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016; 35:e31-e33. DOI: 10.1016/j.ejim.2016.07.010. View

11.

Petrie K, Rief W . Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. Annu Rev Psychol. 2018; 70:599-625. DOI: 10.1146/annurev-psych-010418-102907. View

12.

Desai R, Kim S, Curtis J, Bosco J, Eichelberger B, Barr C . Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2019; 29(7):757-769. DOI: 10.1002/pds.4809. View

13.

Dolinar R, Kohn C, Lavernia F, Nguyen E . The non-medical switching of prescription medications. Postgrad Med. 2019; 131(5):335-341. DOI: 10.1080/00325481.2019.1618195. View

14.

Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M . Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016; 33(12):2160-2172. PMC: 5126187. DOI: 10.1007/s12325-016-0431-5. View

15.

Jacobs I, Singh E, Sewell K, Al-Sabbagh A, Shane L . Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016; 10:937-48. PMC: 4889091. DOI: 10.2147/PPA.S104891. View

16.

Barsky A, Saintfort R, Rogers M, Borus J . Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002; 287(5):622-7. DOI: 10.1001/jama.287.5.622. View